Development of a Health-Related Symptom Index for Participants With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions
4 other identifiers
observational
20
1 country
4
Brief Summary
This trial develops a health-related symptom index for participants with and either treated or monitored for anal high-grade squamous intraepithelial lesions. The health-related quality of life index may help to capture the symptoms and related experiences of living with or being treated for high-grade squamous intraepithelial lesions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Nov 2018
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 6, 2018
CompletedFirst Submitted
Initial submission to the registry
January 22, 2019
CompletedFirst Posted
Study publicly available on registry
February 19, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2020
CompletedResults Posted
Study results publicly available
November 18, 2023
CompletedMarch 7, 2025
March 1, 2025
1.3 years
January 22, 2019
June 30, 2022
March 5, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Development of Spanish-language Version of the Anal Cancer/High-grade Squamous Intraepithelial Lesions (HSIL) Outcomes Research (ANCHOR) Health-related Quality of Life (HRQoL) Index-Round 1 and Round 2
Participants completed A-HRSI, as aurally administered over telephone to indicate whether there were any items or aspects of the instructions that were difficult to understand, and then complete a process of retrospective probing. Summary reports from the Round 1 interview were coded to highlight any instances where a participant indicated that they experienced difficulty with an item or concept within an item. For any item that was reported by at least three participants as difficult for any reason, that item or concept was reviewed to determine whether the difficulty was due to (1) the concept being measured or (2) a translation issue (i.e., register, jargon, or regionalism). These items were revised during a research team panel discussion and used in Round 2 interviews with additional eligible participants. A similar process was used for Round 2.
45-60 minutes during the telephone call in each round.
Study Arms (1)
Health Services Research (cognitive interviews)
Participants take part in cognitive interviews in Spanish over 45-60 minutes.
Interventions
Ancillary studies
Eligibility Criteria
HIV-infected adult men and women with biopsy-proven anal HSIL that was treated in the last 9 months, and who are fluent in Spanish with limited English proficiency.
You may qualify if:
- Human immunodeficiency virus (HIV)-1 infection.
- Biopsy-proven anal HSIL within the prior nine months.
- Participant must have received anal HSIL treatment in the last nine months. If the participant's treatment plan is observation? the participant must have been diagnosed with anal HSIL in the last nine months.
- Life expectancy of greater than 5 years.
- Fluent in Spanish with limited English proficiency, per self-report.
You may not qualify if:
- History of anal cancer.
- Inability to understand a written consent form.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AIDS Malignancy Consortiumlead
- National Cancer Institute (NCI)collaborator
- Memorial Sloan Kettering Cancer Centercollaborator
- The Emmes Company, LLCcollaborator
Study Sites (4)
University of California - San Francisco
San Francisco, California, 94143, United States
Jackson Memorial Hospital
Miami, Florida, 33136, United States
Anal Dysplasia Clinic MidWest
Chicago, Illinois, 60614, United States
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Dr. Thomas M. Atkinson
- Organization
- Memorial Sloan Kettering Cancer Center
Study Officials
- PRINCIPAL INVESTIGATOR
Thomas Atkinson
AIDS Malignancy Consortium
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 22, 2019
First Posted
February 19, 2020
Study Start
November 6, 2018
Primary Completion
March 1, 2020
Study Completion
March 1, 2020
Last Updated
March 7, 2025
Results First Posted
November 18, 2023
Record last verified: 2025-03